Home > Oncology > Best treatment of extensive-stage lung cancer includes PD-L1 inhibitor and etoposide

Best treatment of extensive-stage lung cancer includes PD-L1 inhibitor and etoposide


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Network Open
Reuters Health - 20/11/2020 - The combination of a programmed-cell-death ligand 1 (PD-L1) inhibitor and etoposide-based chemotherapy appears to be the optimal first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC), according to a new systematic review and network meta-analysis. Numerous combinations of agents are used in the first-line treatment of ES-SCLC, but the optimal combination regimen remains unclear. Dr. Li Zhang and colleagues from Sun Yat-sen University Cancer Center, in Guangzhou, China, sought to clarify which first-line combination regimen yields the best tumor response among patients with ES-SCLC in their review of three phase-2 and 11 phase-3 randomized clinical trials involving more than 4,800 patients and eight different regimens. There was no clearly superior treatment in terms of objective response rate, but the combination of a PD-L1 inhibitor (durvalumab or atezolizumab) plus etoposide-platinum chemothera...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on